Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07300280 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Enrollment closed, study ongoing · Secondary endpoints: details revised at 2 of 2 entries · Site details revised · 1 more Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
    • Eligibility criteria expanded, about 4 words
  2. Primary completion date: Oct 7, 2026 to Oct 14, 2026 Completion date: Oct 14, 2026 to Oct 21, 2026v6 Show 1 more changeShow less
    • Completion date: Oct 14, 2026 to Oct 21, 2026
  3. Trial status changed: Active, Not Recruiting → Recruiting Primary completion pushed from Jul 15, 2026 to Oct 7, 2026 · Completion pushed from Jul 22, 2026 to Oct 14, 2026 · Site details revisedv5 Show 3 more changesShow less
    • Primary completion pushed from Jul 15, 2026 to Oct 7, 2026
    • Completion pushed from Jul 22, 2026 to Oct 14, 2026
    • Site details revised
  4. Enrollment target: 30 to 60 Primary endpoints: 8 to 6 · Study arms: 2 to 4v4 Show 2 more changesShow less
    • Primary endpoints: 8 to 6
    • Study arms: 2 to 4

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Feb 17, 2026 to Jul 15, 2026 Completion date: Feb 17, 2026 to Jul 22, 2026v3 Show 1 more changeShow less
    • Completion date: Feb 17, 2026 to Jul 22, 2026
  6. Trial status: Not Yet Recruiting to Active, Not Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.
Trial Details
NCT Number NCT07300280
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov